Delivery Order SPE2DB20D3103-SPE2DB25FP6F3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package at a ceiling value of $1,333.77. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,376.58 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packaging) on August 4, 2025, with completion targeted for August 5, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order valued at $32,773.46 to AmerisourceBergen Drug Corp for Dapagliflozin 10 mg tablets (30-count packaging). The contract was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, and employed firm fixed-price terms with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order represents a competitive award...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $26,330.84, was competitively awarded without set-aside restrictions and carries an ultimate completion date of July 31, 2025. The award represents a child contract issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $38,360.32 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 5 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, competitively awarded delivery order was issued with no set-aside designation and represents performance at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $2,719.49 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets in quantities of 30 for delivery to the Conshohocken, Pennsylvania location. This competitively awarded, firm fixed-price delivery order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025. No set-aside designation was utilized for this procurement. This delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for dapagliflozin 10 mg tablets in a quantity of 30-unit packages, with a ceiling value of $5,581.69. This contract, awarded on August 7, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and carries no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,857.35 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of dapagliflozin 10 mg tablets in quantities of 30 units. The contract represents a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX). Performance will be completed by July 25, 2025, with fulfillment occurring at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 with a ceiling value of $10,996.65. This is a firm fixed price delivery order with no set-aside designation, completed competitively through open procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 28, 2025. This delivery...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6F3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,756.65 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This firm fixed-price contract was competitively awarded without set-aside designation and is scheduled for completion by July 25, 2025. AmerisourceBergen will perform this delivery from its corporate headquarters in Conshohocken, Pennsylvania, where the company maintains significant pharmaceutical distribution operations supporting federal medical procurement. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company's federal contract portfolio demonstrates consistent capability in fulfilling competitive procurement requirements across diverse therapeutic domains, including diabetes medications, neurological treatments, and specialized medical commodities serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 7/24/25 |